Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Oliver Gautschi

Showing results (71-80 of 91) with videos related to

Pageof 10
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 11, 2015
Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohortJulien Mazières, Gérard Zalcman, Lucio Crinò, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 25, 2018
Pembrolizumab as Palliative Immunotherapy in Malignant Pleural MesotheliomaYannis Metaxas, Gareth Rivalland, Laetitia A Mauti, et al.
The European Respiratory Journal|August 12, 2017
Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patientsMyriam Delaunay, Jacques Cadranel, Amélie Lusque, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 9, 2019
Evolution and Clinical Impact of EGFR Mutations in Circulating Free DNA in the BELIEF TrialMiguel-Angel Molina-Vila, Rolf A Stahel, Urania Dafni, et al.
Oncology|May 21, 2026
Decision making in intrathecal therapy for leptomeningeal diseaseSusanne Weindler, Thomas Hundsberger, Alfredo Addeo, et al.
NPJ Precision Oncology|December 18, 2021
Clonal dynamics of BRAF-driven drug resistance in EGFR-mutant lung cancerDiana Schaufler, David F Ast, Hannah L Tumbrink, et al.
Cancer Discovery|December 5, 2013
Cell-autonomous and non-cell-autonomous mechanisms of transformation by amplified FGFR1 in lung cancerFlorian Malchers, Felix Dietlein, Jakob Schöttle, et al.
JCO Precision Oncology|August 17, 2022
Clinical Activity of Mitogen-Activated Protein Kinase-Targeted Therapies in Patients With Non-V600 BRAF-Mutant TumorsMatthew Dankner, Yifan Wang, Rouhi Fazelzad, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 29, 2020
RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven MalignanciesBenjamin J Solomon, Lavinia Tan, Jessica J Lin, et al.
Science Translational Medicine|June 16, 2017
Drugging the catalytically inactive state of RET kinase in RET-rearranged tumorsDennis Plenker, Maximilian Riedel, Johannes Brägelmann, et al.
Pageof 10

Showing results (71-80 of 91) with videos related to

Sort By:
Pageof 10
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 11, 2015
Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohortJulien Mazières, Gérard Zalcman, Lucio Crinò, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 25, 2018
Pembrolizumab as Palliative Immunotherapy in Malignant Pleural MesotheliomaYannis Metaxas, Gareth Rivalland, Laetitia A Mauti, et al.
The European Respiratory Journal|August 12, 2017
Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patientsMyriam Delaunay, Jacques Cadranel, Amélie Lusque, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 9, 2019
Evolution and Clinical Impact of EGFR Mutations in Circulating Free DNA in the BELIEF TrialMiguel-Angel Molina-Vila, Rolf A Stahel, Urania Dafni, et al.
Oncology|May 21, 2026
Decision making in intrathecal therapy for leptomeningeal diseaseSusanne Weindler, Thomas Hundsberger, Alfredo Addeo, et al.
NPJ Precision Oncology|December 18, 2021
Clonal dynamics of BRAF-driven drug resistance in EGFR-mutant lung cancerDiana Schaufler, David F Ast, Hannah L Tumbrink, et al.
Cancer Discovery|December 5, 2013
Cell-autonomous and non-cell-autonomous mechanisms of transformation by amplified FGFR1 in lung cancerFlorian Malchers, Felix Dietlein, Jakob Schöttle, et al.
JCO Precision Oncology|August 17, 2022
Clinical Activity of Mitogen-Activated Protein Kinase-Targeted Therapies in Patients With Non-V600 BRAF-Mutant TumorsMatthew Dankner, Yifan Wang, Rouhi Fazelzad, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 29, 2020
RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven MalignanciesBenjamin J Solomon, Lavinia Tan, Jessica J Lin, et al.
Science Translational Medicine|June 16, 2017
Drugging the catalytically inactive state of RET kinase in RET-rearranged tumorsDennis Plenker, Maximilian Riedel, Johannes Brägelmann, et al.
Pageof 10